PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Latest Information Update: 21 Sep 2025
At a glance
- Drugs AAA 817 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PSMAcTION
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 17 Aug 2025 Planned End Date changed from 3 Jun 2033 to 11 Apr 2033.
- 17 Aug 2025 Planned primary completion date changed from 12 May 2028 to 20 Mar 2028.
- 04 Jul 2025 Planned End Date changed from 31 May 2033 to 3 Jun 2033.